New understanding and treatments for osteoporosis

Endocrine

Volumn 41, Issue 1, 2012, Pages 58-69

  Mazziotti, G ^a,b   Bilezikian, J ^c   Canalis, E ^d,e   Cocchi, D ^a   Giustina, A ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

^c Columbia University ^*  (United States)

^d SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^e UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Cathepsin K; Diabetes; Osteoblasts; Osteoclasts; Osteoporosis; PTH; RANKL; Sclerostin

Indexed keywords

ALENDRONIC ACID; BALICATIB; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CALCIUM SENSING RECEPTOR; CATHEPSIN K INHIBITOR; DENOSUMAB; GLIMEPIRIDE; GLITAZONE DERIVATIVE; INCRETIN; INSULIN; METFORMIN; NOTCH RECEPTOR; ODANACATIB; ONO 5334; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR; PARATHYROID HORMONE[1-34]; PIOGLITAZONE; PLACEBO; RECOMBINANT PARATHYROID HORMONE; ROSIGLITAZONE; SCLEROSTIN; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ADIPOGENESIS; AGING; ANDROGEN DEPRIVATION THERAPY; APOPTOSIS; ARTICLE; BONE DENSITY; BONE EROSION; BONE METABOLISM; BONE METASTASIS; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CARDIOVASCULAR DISEASE; CELLULITIS; DIABETES MELLITUS; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMUR FRACTURE; FRAGILITY FRACTURE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOPARATHYROIDISM; IMMUNE SYSTEM; JAW OSTEONECROSIS; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; OXIDATIVE STRESS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKELETON; SKIN INFECTION; TUMOR CELL; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE;

EID: 84861181435     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-011-9570-2     Document Type: Article

References (118)

1. E.A. Chrischilles, C.D. Butler, C.S. Davis, R.B. Wallace, A model of lifetime osteoporosis impact. Arch. Intern. Med. 51, 2026-2032 (1991)
2. S. Khosla, S. Amin, E. Orwoll, Osteoporosis in men. Endocr. Rev. 29, 441-464 (2008) (Pubitemid 351831508)
3. M. Almeida, L. Han, E. Ambrogini, S.M. Bartell, S.C. Manolagas, Oxidative stress stimulates apoptosis and activates NFkappaB in osteoblastic cells via a PKCbeta/p66shc signaling cascade: counter regulation by estrogens or androgens. Mol. Endocrinol. 24, 2030-2037 (2010)
4. E. Ambrogini, M. Almeida, M. Martin-Millan, J.H. Paik, R.A. Depinho, L. Han, J. Goellner, R.S. Weinstein, R.L. Jilka, C.A. O'Brien, S.C. Manolagas, FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab. 11, 136-146 (2010)
5. 2 while making cholesterol. Endocrinology 149, 3264-3266 (2008) (Pubitemid 351919569)
6. M. Almeida, M. Martin-Millan, E. Ambrogini III, R. Bradsher, L. Han, X.D. Chen, P.K. Roberson, R.S. Weinstein, C.A. O'Brien, R.L. Jilka, S.C. Manolagas, Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERalpha. J. Bone Miner. Res. 25, 769-781 (2010)
7. S.C. Manolagas, From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr. Rev. 31, 266-300 (2010)
8. S. Zanotti, E. Canalis, Notch and the skeleton. Mol. Cell. Biol. 30, 886-896 (2010)
9. Y. Nam, P. Sliz, L. Song, J.C. Aster, S.C. Blacklow, Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell 124, 973-983 (2006) (Pubitemid 43344237)
10. V. Deregowski, E. Gazzerro, L. Priest, S. Rydziel, E. Canalis, Notch 1 overexpression inhibits osteoblastogenesis by suppressing Wnt/beta-Catenin but not bone morphogenetic protein signaling. J. Biol. Chem. 281, 6203-6210 (2006) (Pubitemid 43847550)
11. S. Zanotti, A. Smerdel-Ramoya, L. Stadmeyer, D. Durant, F. Radtke, E. Canalis, Notch inhibits osteoblast differentiation and causes osteopenia. Endocrinology 149, 3890-3899 (2008)
12. M.J. Hilton, X. Tu, X. Wu, S. Bai, H. Zhao, T. Kobayashi, H.M. Kronenberg, S.L. Teitelbaum, F.P. Ross, R. Kopan, F. Long, Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat. Med. 14, 306-314 (2008) (Pubitemid 351347911)
13. N. Sethi, X. Dai, C.G. Winter, J. Kang, Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 19, 192-205 (2011)
14. J. Tao, A. Erez, B. Lee, One NOTCH further: Jagged 1 in bone metastasis. Cancer Cell 19, 159-161 (2011)
15. S. Zanotti, A. Smerdel-Ramoya, E. Canalis, Reciprocal regulation of Notch and nuclear factor of activated T-cells (NFAT) c1 transactivation in osteoblasts. J. Biol. Chem. 286, 4576-4588 (2011)
16. B. Isidor, P. Lindenbaum, O. Pichon, S. Bézieau, C. Dina, S. Jacquemont, D. Martin-Coignard, C. Thauvin-Robinet, M. Le Merrer, J.L. Mandel, A. David, L. Faivre, V. Cormier-Daire, R. Redon, C. Le Caignec, Truncating mutations in the last exon of NOTCH2 cause a rare skeletal disorder with osteoporosis. Nat. Genet. 43, 306-308 (2011)
17. M.A. Simpson, M.D. Irving, E. Asilmaz, M.J. Gray, D. Dafou, F.V. Elmslie, S. Mansour, S.E. Holder, C.E. Brain, B.K. Burton, K.H. Kim, R.M. Pauli, S. Aftimos, H. Stewart, C.A. Kim, M. Holder-Espinasse, S.P. Robertson, W.M. Drake, R.C. Trembath, Mutations in NOTCH2 cause Hajdu-Cheney syndrome, a disorder of severe and progressive bone loss. Nat. Genet. 43, 303-305 (2011)
18. M.M. Dvorak, A. Siddiqua, D.T. Ward, D.H. Carter, S.L. Dallas, E.F. Nemeth, D. Riccardi, Physiological changes in extracellular calcium concentration directly control osteoblast function in the absence of calciotropic hormones. Proc. Natl Acad. Sci. USA 101, 5140-5145 (2004) (Pubitemid 38469215)
19. N. Chattopadhyay, S. Yano, J. Tfelt-Hansen, P. Rooney, D. Kanuparthi, S. Bandyopadhyay, X. Ren, E. Terwilliger, E.M. Brown, Mitogenic action of calcium-sensing receptor on rat calvarial osteoblasts. Endocrinology 145, 3451-3462 (2004) (Pubitemid 38830018)
20. T. Kameda, H. Mano, Y. Yamada, H. Takai, N. Amizuka, M. Kobori, N. Izumi, H. Kawashima, H. Ozawa, K. Ikeda, A. Kameda, Y. Hakeda, M. Kumegawa, Calcium-sensing receptor in mature osteoclasts, which are bone resorbing cells. Biochem. Biophys. Res. Commun. 245, 419-422 (1998) (Pubitemid 28418516)
21. E.M. Brown, R.J. MacLeod, Extracellular calcium sensing and extracellular calcium signaling. Physiol. Rev. 81, 239-297 (2001) (Pubitemid 32096177)
22. K. Ballen, Targeting the stem cell niche: squeezing blood from bones. Bone Marrow Transplant. 39, 655-660 (2007) (Pubitemid 46813581)
23. E. Canalis, Novel treatments for osteoporosis. J. Clin. Invest. 106, 177-179 (2000) (Pubitemid 30483119)
24. P.J. Marie, The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis. Bone 46, 571-576 (2010)
25. E. Canalis, A. Giustina, J.P. Bilezikian, Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med. 357, 905-916 (2007)
26. R. Pacifici, T cells: critical bone regulators in health and disease. Bone 47, 461-471 (2010)
27. Y. Gao, X. Wu, M. Terauchi, F. Grassi, S. Galley, X. Yang, M.N. Weitzmann, R. Pacifici, T cells potentiate PTH-induced cortical bone loss through CD40L signaling. Cell Metab. 8, 132-145 (2008)
28. H. Tawfeek, B. Bedi, J.Y. Li, J. Adams, T. Kobayashi, M.N. Weitzmann, H.M. Kronenberg, R. Pacifici, Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss. PLoS ONE 5, e12290 (2010)
29. R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, J.Y. Reginster, A.B. Hodsman, E.F. Eriksen, S. Ish-Shalom, H.K. Genant, O. Wang, B.H. Mitlak, Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434-1441 (2001) (Pubitemid 32402100)
30. S.L. Greenspan, H.G. Bone, M.P. Ettinger, D.A. Hanley, R. Lindsay, J.R. Zanchetta, C.M. Blosch, A.L. Mathisen, S.A. Morris, T.B. Marriott, Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann. Intern. Med. 146, 326-339 (2007) (Pubitemid 351650593)
31. J.P. Bilezikian, Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr. Osteoporos. Rep. 6, 24-30 (2008)
32. K.G. Saag, E. Shane, S. Boonen, F. Marín, D.W. Donley, K.A. Taylor, G.P. Dalsky, R. Marcus, Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 357, 2028-2039 (2007) (Pubitemid 350106710)
33. K.G. Saag, J.R. Zanchetta, J.P. Devogelaer, R.A. Adler, R. Eastell, K. See, J.H. Krege, K. Krohn, M.R. Warner, Effects of teriparatide versus alendronate for treating glucocorticoidinduced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 60, 3346-3355 (2009)
34. F. Cosman, R.A. Wermers, C. Recknor, K.F. Mauck, L. Xie, E.V. Glass, J.H. Krege, Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronte or raloxifene: differences between stopping and continuing the antiresorptive agent. J. Clin. Endocrinol. Metab. 94, 3772-3780 (2009)
35. J.S. Finkelstein, J.J. Wyland, B.Z. Leder, S.M. Burnett-Bowie, H. Lee, H. Jüppner, R.M. Neer, Effects of teriparatide retreatment in osteoporotic men and women. J. Clin. Endocrinol. Metab. 94, 2495-2501 (2009)
36. N.E. Cusano, J.P. Bilezikian, Teriparatide: variations on the theme of a 2-year therapeutic course. BoneKey 7, 84-87 (2010)
37. N.E. Cusano, J.P. Bilezikian, Combination antiresorptive and osteoanabolic therapy for osteoporosis: we are not there yet. Curr. Med. Res. Opin. (2011) [Epub ahead of print, PMID 21740288]
38. J. Compston, The use of combination therapy in the treatment of postmenopausal osteoporosis. Endocrine (2011) [Epub ahead of print]
39. S. Boonen, K. Milison, E. Gielen, D. Vanderschueren, Sequential therapy in the treatment of osteoporosis. Curr. Med. Res. Opin. 27, 1149-1155 (2011)
40. D.M. Black, S.L. Greenspan, K.E. Ensrud, L. Palermo, J.A. McGowan, T.F. Lang, P. Garnero, M.L. Bouxsein, J.P. Bilezikian, C.J. Rosen, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349, 1207-1215 (2003) (Pubitemid 37152030)
41. F. Cosman, E.F. Eriksen, C. Recknor, P.D. Miller, N. Guañabens, C. Kasperk, P. Papanastasiou, A. Readie, H. Rao, J.A. Gasser, C. Bucci-Rechtweg, S. Boonen, Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J. Bone Miner. Res. 26, 503-511 (2011)
42. J.P. Bilezikian, A. Khan, J.T. Potts Jr., M.L. Brandi, B.L. Clarke, D. Shoback, H. Jüppner, P. D'Amour, J. Fox, L. Rejnmark, L. Mosekilde, M.R. Rubin, D. Dempster, R. Gafni, M.T. Collins, J. Sliney, J. Sanders, Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target organ involvement, treatment, and challenges for future research. J. Bone Miner. Res. (2011). doi: 10.1002/jbmr.483. [Epub ahead of print]
43. K.K. Winer, N. Sinaii, J. Reynolds, D. Peterson, K. Dowdy, G.B. Cutler Jr, Long term therapy of 12 children with chronic hypoparathyroidism: a randomized trail comparing synthetic human parathyroid hormone (1-34) vs calcitriol and calcium. J. Clin. Endocrinol. Metab. 95, 2680-2688 (2010)
44. M.R. Rubin, J.P. Bilezikian, Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement. Braz. Arch. Endocrinol. Metab. 54, 220-226 (2010)
45. T. Sikjaer, L. Rejnmark, L. Rolighed, L. Heickendorff, L. Mosekilde, The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism-A randomized, placebo-controlled study. J. Bone Miner. Res. 26, 2358-2370 (2011)
46. W.J. Boyle, W.S. Simonet, D.L. Lacey, Osteoclast differentiation and activation. Nature 423, 337-342 (2003) (Pubitemid 40852708)
47. W.S. Simonet, D.L. Lacey, C.R. Dunstan, M. Kelley, M.S. Chang, R. Lüthy, H.Q. Nguyen, S. Wooden, L. Bennett, T. Boone, G. Shimamoto, M. DeRose, R. Elliott, A. Colombero, H.L. Tan, G. Trail, J. Sullivan, E. Davy, N. Bucay, L. Renshaw-Gegg, T.M. Hughes, D. Hill, W. Pattison, P. Campbell, S. Sander, G. Van, J. Tarpley, P. Derby, R. Lee, W.J. Boyle, Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319 (1997) (Pubitemid 27199902)
48. N. Bucay, I. Sarosi, C.R. Dunstan, S. Morony, J. Tarpley, C. Capparelli, S. Scully, H.L. Tan, W. Xu, D.L. Lacey, W.J. Boyle, W.S. Simonet, Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12, 1260-1268 (1998) (Pubitemid 28213402)
49. L.C. Hofbauer, C.A. Kühne, V. Viereck, The OPG/RANKL/ RANK system in metabolic bone diseases. J. Musculoskelet. Neuronal Interact. 4, 268-275 (2004) (Pubitemid 39504354)
50. P.J. Kostenuik, C. Capparelli, S. Morony, S. Adamu, G. Shimamoto, V. Shen, D.L. Lacey, C.R. Dunstan, OPG and PTH- (1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 142, 4295-4304 (2001) (Pubitemid 32907057)
51. P.J. Bekker, D. Holloway, A. Nakanishi, M. Arrighi, P.T. Leese, C.R. Dunstan, The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 16, 348-360 (2001) (Pubitemid 32105416)
52. P.J. Bekker, D.L. Holloway, A.S. Rasmussen, R. Murphy, S.W. Martin, P.T. Leese, G.B. Holmes, C.R. Dunstan, A.M. DePaoli, A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 19, 1059-1066 (2004) (Pubitemid 41110556)
53. H.G. Bone, M.A. Bolognese, C.K. Yuen, D.L. Kendler, P.D. Miller, Y.C. Yang, L. Grazette, J. San Martin, J.C. Gallagher, Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J. Clin. Endocrinol. Metab. 96, 972-980 (2011)
54. T.D. Rachner, S. Khosla, L.C. Hofbauer, Osteoporosis: now and the future. Lancet 377, 1276-1287 (2011)
55. S.R. Cummings, J. San Martin, M.R. McClung, E.S. Siris, R. Eastell, I.R. Reid, P. Delmas, H.B. Zoog, M. Austin, A. Wang, S. Kutilek, S. Adami, J. Zanchetta, C. Libanati, S. Siddhanti, C. Christiansen, Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756-765 (2009)
56. S. Boonen, J.D. Adachi, Z. Man, S.R. Cummings, K. Lippuner, O. Törring, J.C. Gallagher, J. Farrerons, A. Wang, N. Franchimont, J. San Martin, A. Grauer, M. McClung, Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J. Clin. Endocrinol. Metab. 96, 1727-1736 (2011)
57. C. von Keyserlingk, R. Hopkins, A. Anastasilakis, K. Toulis, R. Goeree, J.E. Tarride, F. Xie, Clinical efficacy and safety of Denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis. Semin. Arthritis Rheum. 41, 178-186 (2011)
58. G. Mazziotti, E. Canalis, A. Giustina, Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med. 123, 877-884 (2010)
59. M.R. Smith, B. Egerdie, N. Hernández Toriz, R. Feldman, T.L. Tammela, F. Saad, J. Heracek, M. Szwedowski, C. Ke, A. Kupic, B.Z. Leder, C. Goessl, Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745-755 (2009)
60. G.K. Ellis, H.G. Bone, R. Chlebowski, D. Paul, S. Spadafora, J. Smith, M. Fan, S. Jun, Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J. Clin. Oncol. 26, 4875-4882 (2008)
61. O. Sezer, U. Heider, I. Zavrski, C.A. Kühne, L.C. Hofbauer, RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101, 2094-2098 (2003) (Pubitemid 36302042)
62. U. Heider, C. Langelotz, C. Jakob, I. Zavrski, C. Fleissner, J. Eucker, K. Possinger, L.C. Hofbauer, O. Sezer, Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin. Cancer Res. 9, 1436-1440 (2003) (Pubitemid 36418398)
63. S. Roux, V. Meignin, J. Quillard, G. Meduri, A. Guiochon-Mantel, J.P. Fermand, E. Milgrom, X. Mariette, RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br. J. Haematol. 117, 86-92 (2002) (Pubitemid 34304425)
64. N. Giuliani, S. Colla, R. Sala, M. Moroni, M. Lazzaretti, S. La Monica, S. Bonomini, M. Hojden, G. Sammarelli, S. Barillè, R. Bataille, V. Rizzoli, Human myeloma cells stimulate the receptor activator of NF-kappaB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 100, 4615-4621 (2002) (Pubitemid 35429706)
65. G.D. Roodman, Mechanisms of bone metastasis. N. Engl. J. Med. 350, 1655-1664 (2004)
66. A.T. Stopeck, A. Lipton, J.J. Body, G.G. Steger, K. Tonkin, R.H. de Boer, M. Lichinitser, Y. Fujiwara, D.A. Yardley, M. Viniegra, M. Fan, Q. Jiang, R. Dansey, S. Jun, A. Braun, Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28, 5132-5139 (2010)
67. K. Fizazi, M. Carducci, M. Smith, R. Damião, J. Brown, L. Karsh, P. Milecki, N. Shore, M. Rader, H. Wang, Q. Jiang, S. Tadros, R. Dansey, C. Goessl, Denosumab versus zoledronic acid for treatment of bone metastases in men with castrationresistant prostate cancer: a randomised, double-blind study. Lancet 377, 813-822 (2011)
68. D.H. Henry, L. Costa, F. Goldwasser, V. Hirsh, V. Hungria, J. Prausova, G.V. Scagliotti, H. Sleeboom, A. Spencer, S. Vadhan-Raj, R. von Moos, W. Willenbacher, P.J. Woll, J. Wang, Q. Jiang, S. Jun, R. Dansey, H. Yeh, Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 29, 1125-1132 (2011)
69. A.K. Gough, J. Lilley, S. Eyre, R.L. Holder, P. Emery, Generalized bone loss in patients with rheumatoid arthritis. Lancet 344, 23-27 (1994) (Pubitemid 24199420)
70. K. Nemeth, M. Schoppet, N. Al-Fakhri, S. Helas, R. Jessberger, L.C. Hofbauer, C. Goettsch, The role of osteoclast-associated receptor in osteoimmunology. J. Immunol. 186, 13-18 (2011)
71. E. Romas, N.A. Sims, D.K. Hards, M. Lindsay, J.W. Quinn, P.F. Ryan, C.R. Dunstan, T.J. Martin, M.T. Gillespie, Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am. J. Pathol. 161, 1419-1427 (2002)
72. S.B. Cohen, R.K. Dore, N.E. Lane, P.A. Ory, C.G. Peterfy, J.T. Sharp, D. van der Heijde, L. Zhou, W. Tsuji, R. Newmark, Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebocontrolled, phase II clinical trial. Arthritis Rheum. 58, 1299-1309 (2008) (Pubitemid 351705919)
73. M.P. Whyte, The long and the short of bone therapy. N. Engl. J. Med. 354, 860-863 (2006) (Pubitemid 43290927)
74. D.H. Jones, T. Nakashima, O.H. Sanchez, I. Kozieradzki, S.V. Komarova, I. Sarosi, S. Morony, E. Rubin, R. Sarao, C.V. Hojilla, V. Komnenovic, Y.Y. Kong, M. Schreiber, S.J. Dixon, S.M. Sims, R. Khokha, T. Wada, J.M. Penninger, Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692-696 (2006)
75. N. Frazl-Zelman, A. Valenta, P. Roschger, A. Nader, B.D. Gelb, P. Fratzl, K. Klaushofer, Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis. J. Clin. Endocrinol. Metab. 89, 1538-1547 (2004) (Pubitemid 38507900)
76. J.Y. Gauthier, N. Chauret, W. Cromlish, S. Desmarais, T. Duong le, J.P. Falgueyret, D.B. Kimmel, S. Lamontagne, S. Léger, T. LeRiche, C.S. Li, F. Massé, D.J. McKay, D.A. Nicoll-Griffith, R.M. Oballa, J.T. Palmer, M.D. Percival, D. Riendeau, J. Robichaud, G.A. Rodan, S.B. Rodan, C. Seto, M. Thérien, V.L. Truong, M.C. Venuti, G. Wesolowski, R.N. Young, R. Zamboni, W.C. Black, The discovery of odanacatib (MK0822), a selective inhibitor of cathepsin-K. Bioorg. Med. Chem. Lett. 18, 923-928 (2008) (Pubitemid 351179363)
77. S. Nagase, M. Ohyama, Y. Hashimoto, M. Small, T. Kuwayama, S. Deacon, Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K inhibitor, ONO-5334, in an ascending multiple-dose, phase 1 study. J. Clin. Pharmacol. (2011) [Epub ahead of print]
78. H.G. Bone, M.R. McClung, C. Roux, R.R. Recker, J.A. Eisman, N. Verbruggen, C.M. Hustad, C. DaSilva, A.C. Santora, B.A. Ince, Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J. Bone Miner. Res. 25, 937-947 (2010)
79. S.E. Papapoulos, Targeting sclerostin as potential treatment of osteoporosis. Ann. Rheum. Dis. 70(Suppl 1), 19-22 (2011)
80. X. Li, M.S. Ominsky, K.S. Warmington, S. Morony, J. Gong, J. Cao, Y. Gao, V. Shalhoub, B. Tipton, R. Haldankar, Q. Chen, A. Winters, T. Boone, Z. Geng, Q.T. Niu, H.Z. Ke, P.J. Kostenuik, W.S. Simonet, D.L. Lacey, C. Paszty, Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res. 24, 578-588 (2009)
81. M.S. Ominsky, F. Vlasseros, J. Jolette, S.Y. Smith, B. Stouch, G. Doellgast, J. Gong, Y. Gao, J. Cao, K. Graham, B. Tipton, J. Cai, R. Deshpande, L. Zhou, M.D. Hale, D.J. Lightwood, A.J. Henry, A.G. Popplewell, A.R. Moore, M.K. Robinson, D.L. Lacey, W.S. Simonet, C. Paszty, Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density and bone strength. J. Bone Miner. Res. 25, 948-959 (2010)
82. D. Padhi, G. Jang, B. Stouch, L. Fang, E. Posvar, Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 26, 19-26 (2011)
83. R.H. Giles, J.K. van Es, H. Clevers, Caught up in a Wnt storm: Wnt signalling in cancer. Biochem. Biophys. Acta 1653, 1-24 (2003) (Pubitemid 36627817)
84. M. Kansara, M. Tsang, L. Kodjabachian, N.A. Sims, M.K. Trivett, M. Ehrich, A. Dobrovic, J. Slavin, P.F. Choong, P.J. Simmons, I.B. Dawid, D.M. Thomas, Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J. Clin. Invest. 119, 837-851 (2009)
85. A.A. Khan, G.K.B. Sandor, E. Dore, A.D. Morrison, M. Alsahli, F. Amin, E. Peters, D.A. Hanley, S.R. Chaudry, B. Lentle, D.W. Dempster, F.H. Glorieux, A.J. Neville, R.M. Talwar, C.M. Clokie, M.A. Mardini, T. Paul, S. Khosla, R.G. Josse, S. Sutherland, D.K. Lam, R.P. Carmichael, N. Blanas, D. Kendler, S. Petak, L.G. Ste-Marie, J. Brown, A.W. Evans, L. Rios, J.E. Compston, Bisphosphonate associated osteonecrosis of the jaw. J. Reumathol. 36, 478-490 (2009)
86. J.C. Lo, F.S. O'Ryan, N.P. Gordon, J. Yang, R.L. Hui, D. Martin, M. Hutchinson, P.V. Lathon, G. Sanchez, P. Silver, M. Chandra, C.A. McCloskey, J.A. Staffa, M. Willy, J.V. Selby, A.S. Go, Predicting risk of osteonecrosis of the jaw with oral bisphosphonate exposure (PROBE) investigators. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J. Oral Maxillofac. Surg. 68, 243-253 (2010)
87. S.L. Ruggiero, T.B. Dodson, L.A. Assael, R. Landesberg, R.E. Marx, B. Mehrotra, American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonates-related osteonecrosis of the jaws: 2009 update. J. Oral Maxillofac. Surg. 67(Suppl 5), 2-12 (2009)
88. J.E. Compston, Bisphosphonates and atypical femoral fractures: a time for reflection. Maturitas 65, 3-4 (2010)
89. E.M. Lewiecki, Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs 71, 791-814 (2011)
90. M. Pazianas, J. Compston, C.L. Huang, Atrial fibrillation and bisphosphonate therapy. J. Bone Miner. Res. 25, 2-10 (2010)
91. E. Barrett-Connor, A.S. Swern, C.M. Hustad, H.G. Bone, U.A. Liberman, S. Papapoulos, H. Wang, A. de Papp, A.C. Santora, Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. Osteoporos. Int. (2011) [Epub ahead of print]
92. W. Wang, X. Zhang, J. Zheng, J. Yang, High glucose stimulates adipogenic and inhibits osteogenic differentiation in MG- 63 cells through cAMP/protein kinase A/extracellular signalregulated kinase pathway. Mol. Cell. Biochem. 338, 115-122 (2010)
93. R.A. Kayal, D. Tsatsas, M.A. Bauer, B. Allen, M.O. Al-Sebaei, S. Kakar, C.W. Leone, E.F. Morgan, L.C. Gerstenfeld, T.A. Einhorn, D.T. Graves, Diminished bone formation during diabetic fracture healing is related to the premature resorption of cartilage associated with increased osteoclast activity. J. Bone Miner. Res. 22, 560-568 (2007) (Pubitemid 47457433)
94. Y. Hamada, S. Kitazawa, R. Kitazawa, K. Kono, S. Goto, H. Komaba, H. Fujii, Y. Yamamoto, H. Yamamoto, M. Usami, M. Fukagawa, The effects of the receptor for advanced glycation end products (RAGE) on bone metabolism under physiological and diabetic conditions. Endocrine 38, 369-376 (2010)
95. M. Alikhani, Z. Alikhani, C. Boyd, C.M. MacLellan, M. Raptis, R. Liu, N. Pischon, P.C. Trackman, L. Gerstenfeld, D.T. Graves, Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 40, 345 (2007)
96. A. Giustina, G. Mazziotti, E. Canalis, Growth hormone, insulinlike growth factors, and the skeleton. Endocr. Rev. 29, 535-559 (2008)
97. A. Räkel, O. Sheehy, E. Rahme, J. LeLorier, Osteoporosis among patients with type 1 and type 2 diabetes. Diabetes Metab. 34, 193-205 (2008)
98. P. Vestergaard, L. Rejnmark, L. Mosekilde, Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48, 1292-1299 (2005) (Pubitemid 41186093)
99. P. Vestergaard, Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a metaanalysis. Osteoporos. Int. 18, 427-444 (2007) (Pubitemid 46354916)
100. S. Bonadonna, G. Mazziotti, M. Nuzzo, A. Bianchi, A. Fusco, L. De Marinis, A. Giustina, Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J. Bone Miner. Res. 20, 1837-1844 (2005) (Pubitemid 41361885)
101. G. Mazziotti, A. Angeli, J.P. Bilezikian, E. Canalis, A. Giustina, Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol. Metab. 17, 144-149 (2006)
102. G. Mazziotti, A. Bianchi, S. Bonadonna, M. Nuzzo, V. Cimino, A. Fusco, L. De Marinis, A. Giustina, Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J. Bone Miner. Res. 21, 520-528 (2006)
103. G. Mazziotti, A. Bianchi, S. Bonadonna, V. Cimino, I. Patelli, A. Fusco, A. Pontecorvi, L. De Marinis, A. Giustina, Prevalence of vertebral fractures in men with acromegaly. J. Clin. Endocrinol. Metab. 93, 4649-4655 (2008)
104. G. Mazziotti, M. Gola, A. Bianchi, T. Porcelli, A. Giampietro, V. Cimino, M. Doga, C. Gazzaruso, L. De Marinis, A. Giustina, Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine 40, 102-108 (2011)
105. G. Mazziotti, T. Mancini, M. Mormando, E. De Menis, A. Bianchi, M. Doga, T. Porcelli, P.P. Vescovi, L. De Marinis, A. Giustina, High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary 14, 299-306 (2011)
106. G. Mazziotti, T. Porcelli, M. Mormando, E. De Menis, A. Bianchi, C. Mejia, T. Mancini, L. De Marinis, A. Giustina, Vertebral fractures in males with prolactinoma. Endocrine 39, 288-293 (2011)
107. M. Viégas, C. Costa, A. Lopes, L. Griz, M.A. Medeiro, F. Bandeira, Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their relationship with duration of the disease and chronic complications. J. Diabetes Complications 25, 216-221 (2011)
108. P. Vestergaard, Risk of newly diagnosed type 2 diabetes is reduced in users of alendronate. Calcif. Tissue. Intern. (2011) [Epub ahead of print]
109. M.S. Molinuevo, L. Schurman, A.D. McCarthy, A.M. Cortizo, M.J. Tolosa, M.V. Gangoiti, V. Arnol, C. Sedlinsky, Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. J. Bone Miner. Res. 25, 211-221 (2010)
110. P. Ma, B. Gu, J. Ma, X. Wu, J. Cao, H. Liu, Glimepiride induces proliferation and differentiation of rat osteoblasts via the PI3- kinase/Akt pathway. Metabolism 59, 359-366 (2010)
111. V. Gopalakrishnan, R.C. Vignesh, J. Arunakaran, M.M. Aruldhas, N.E. Srinivasan, Effects of glucose and its modulation by insulin and estradiol on BMSC differentiation into osteoblastic lineages. Biochem. Cell Biol. 84, 93-101 (2006)
112. B. Nuche-Berenguer, S. Portal-Núñez, P. Moreno, N. González, A. Acitores, A. López-Herradón, P. Esbrit, I. Valverde, M.L. Villanueva-Peñacarrillo, Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. J. Cell. Physiol. 225, 585-592 (2010)
113. A. Grey, Skeletal consequences of thiazolidinedione therapy. Osteoporos. Int. 19, 129-137 (2008)
114. Y.K. Loke, S. Singh, C.D. Furberg, Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. Can. Med. Assoc. J. 180, 32-39 (2009)
115. T. Mancini, G. Mazziotti, M. Doga, R. Carpinteri, N. Simetovic, P.P. Vescovi, A. Giustina, Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone 45, 784-788 (2009)
116. I.J. Douglas, S.J. Evans, S. Pocock, L. Smeeth, The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med. 6, e1000154 (2009)
117. C.R. Dormuth, G. Carney, B. Carleton, K. Bassett, J.M. Wright, Thiazolidinediones and fractures in men and women. Arch. Intern. Med. 169, 1395-1402 (2009)
118. I. Kanazawa, T. Yamaguchi, M. Yamamoto, M. Yamauchi, S. Yano, T. Sugimoto, Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. Eur. J. Endocrinol. 160, 265-273 (2009)